302924-75-0

Upstream product

• 109715-47-1 (R)-3-(tert-butyldimethylsilyloxy)-1-butanol 
• 85960-55-0 (S)-(2-phenylmethoxyethyl)oxirane 
• 94426-72-9 2-(2-(benzyloxy)ethyl)oxirane 
• 70388-33-9 4-benzyloxybut-1-ene 
• 100-39-0 benzyl bromide 
• 85960-54-9 (S)-toluene-4-sulfonic acid 3-benzyloxy-2-hydroxy-propyl ester 
• 71998-69-1 (S)-4-benzyloxy-1,2-butanediol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 77564-44-4 (R)-(+)-1,3-butanediol 1-benzyl ether 
• 105729-41-7 3-(R)-t-butyldimethylsilyloxybutanoic acid 
• 104524-19-8 methyl (R)-(-)-3-(tert-butyldimethylsilyloxy)butyrate 

Downstream Products

• 77564-44-4 (R)-(+)-1,3-butanediol 1-benzyl ether 
• 106539-39-3 [(1R)-3-benzyloxy-1-methylpropyl] acetate 

Relevant academic research and scientific papers

First stereoselective total synthesis of ophiocerins B and C

An elegant synthesis of ophiocerins B and C is accomplished for the first time with 3R,4R,6R and 3S,4S,6R-configuration. Of these three stereogenic centers, the C-3/C-4 vic-diol was created by Sharpless asymmetric dihydroxylation, while the C-6 stereocent

ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE

Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER

Disclosed herein are acylated active agents and methods of their use, e.g., for modulating a cancer marker or for treating cancer.

MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME

Multibiotic agents are disclosed. The multibiotic agents may contain two or more moieties linked through bonds cleavable in vivo. The bonds cleavable in vivo can be ester bonds, amide bonds, azo bonds, glycosidic bonds, carbonate linkers, or carbamate linkers. The moieties can be alcohol cores, amine cores, and/or acyls. Also disclosed are compositions containing multibiotic agents and methods of using the multibiotic agents.

First Synthesis and Characterization of Stereoisomers of Choleretic Drug Dihydroxydibutylether

Dihydroxydibutylether (DHBE) is a choleretic drug used for the treatment of gallstone and hepatic disorders due to its choleretic activity and hepatoprotective action. The drug is a mixture of three regioisomers. The main regioisomer 3-(3-hydroxylbutoxy)-

First stereoselective total synthesis of Neocosmosin A: A facile approach

First stereoselective concise synthesis of Neocosmosin A, with in vitro binding affinity for human opioid and cannabinoid receptors, has been reported using readily available starting materials such as methylacetoacetate, cyclohexanone, and homoallyl alco

Acceleration of hetero-Michael reaction by symmetrical pentacyclic guanidines

Symmetrical pentacyclic guanidines 1a-c and 2 which contain the core skeleton of 13,14,15-isocrmbescidine 800, have been synthesized. In the presence of catalytic amounts of these guanidines 1, the reaction rate of the conjugate addition of pyrrolidine (9) to γ-crotonolactone (10) could be enhanced depending upon the size of the cavities and substituents on tetrahydropyran rings of 1 and 2.